Latest News from Origin
Origin Capital News: Q1 2018
Read about Origin’s latest portfolio activity and recent performance data here.
Myrtle – new unquoted investment
Myrtle produces tools for instantiation of software programmes, particularly deep learning algorithms, in silicon (FPGAs). This market area is experiencing high growth as data centres are increasingly used for high-speed, remote processing. Origin invested in November 2017 as part of a round led by the Cambridge Angels network. Read more…
Lintbells – successful PE exit
We have had a very good exit from our investment in pet health business Lintbells, following the purchase of a significant interest in the company by Inflexion Private Equity. Terms of the transaction have not been disclosed. Read more…
Origin adds Ubio to basket
Origin Capital has invested in web automation company Ubio, in a round led by existing investors. Ubio’s technology aims to improve basket conversion rates for metasearch sites, including those operating in the travel and financial products markets.
Origin Capital News Q2 2017
Read about latest portfolio activity, performance data and the golf-day washout here.
Monica exit delivers 5.5x money at over 150% IRR
Origin is delighted to announce the sale of Monica Healthcare to global life sciences business GE Healthcare. Origin invested in Monica in November 2014, and again in March 2016. The exit has delivered over 5.5x returns to Origin and its co-investors, and the relatively short average holding period has lead to an exceptionally strong IRR.
ARM invests in Blu Wireless Technology
Origin portfolio company has secured a significant corporate investment from ARM, one of the world’s leading semiconductor technology companies. The investment is part of a wider strategic partnership – read more here…
Spectral Edge: Computational image processing – new investment
Spectral Edge is using computational techniques to combine visual spectrum and infra-red data from the same image. This can significantly improve clarity, detail and colour representation. Such improvements are much sought after by phone manufacturers and others. We participated in an early-stage round alongside institutional and angel investors.
Scancell realisation – 5.5x money
Scancell develops DNA-based vaccines for cancer therapy, and potentially other indications. We invested in the company in three separate funding rounds, in 2008, 2010 and 2011. We sold our holding in the latter half of 2015, realising just over 5.5x cost, equating to an IRR over the life of the investment of 37% pre-EIS benefits, or 44% including them.
Naturemetrics – New investment in genetic environmental monitoring
Naturemetrics is using DNA and other genetic approaches to assess the presence of organisms in natural environments. We have participated in a seed-funding round alongside the Iceni seedcorn fund and several individual angel investors.